Quarterly report pursuant to Section 13 or 15(d)

Licensing, Collaborative and Other Arrangements (Details)

v2.4.0.6
Licensing, Collaborative and Other Arrangements (Details) (USD $)
In Millions, unless otherwise specified
6 Months Ended
Jun. 30, 2012
Development Milestone [Member]
 
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]  
Amount due upon achievement of milestone $ 8.5
Sales Milestone [Member]
 
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]  
Amount due upon achievement of milestone 15.1
Collaborative Arrangement [Member]
 
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]  
Number of fixed-dose combination product candidates included in a portfolio of antihypertensive products from Servier 3
Number of patients to be enrolled in trial 816
License fees paid $ 1.5